HCW Financial Statements From 2010 to 2026

HCWB Stock  USD 1.39  0.06  4.51%   
HCW Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing HCW Biologics' valuation are provided below:
Gross Profit
166.6 K
Market Capitalization
5.4 M
Enterprise Value Revenue
24.0229
Revenue
832.8 K
Earnings Share
(16.41)
We have found one hundred twenty available fundamental trends for HCW Biologics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of HCW Biologics regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself next year. As of January 22, 2026, Market Cap is expected to decline to about 756.1 M. In addition to that, Enterprise Value is expected to decline to about 765.9 M

HCW Biologics Total Revenue

3.73 Million

Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 838.9 K or Interest Expense of 1.4 M, as well as many indicators such as Price To Sales Ratio of 295, Dividend Yield of 0.0 or Days Sales Outstanding of 144. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
  
Build AI portfolio with HCW Stock
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

HCW Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.8 M34.8 M20.2 M
Slightly volatile
Other Current Liabilities1.5 M1.1 MM
Slightly volatile
Total Current Liabilities35.8 M34.1 M7.4 M
Slightly volatile
Property Plant And Equipment Net27.7 M26.3 M7.7 M
Slightly volatile
Accounts Payable27 M25.7 M5.1 M
Slightly volatile
Cash7.8 M4.2 MM
Very volatile
Non Current Assets Total14.2 M28.2 M8.1 M
Slightly volatile
Non Currrent Assets Other24.3 K25.6 K72.9 K
Pretty Stable
Other Assets218.8 K384 K139.7 K
Slightly volatile
Cash And Short Term InvestmentsM4.2 M9.8 M
Pretty Stable
Common Stock Total Equity4.3 K4.1 K1.6 K
Slightly volatile
Common Stock Shares Outstanding40.3 M44.6 M37.3 M
Slightly volatile
Liabilities And Stockholders Equity33.8 M34.8 M20.2 M
Slightly volatile
Non Current Liabilities Total8.9 M8.5 M2.5 M
Slightly volatile
Other Current Assets695.3 K397.5 K728 K
Very volatile
Other Stockholder Equity62.8 M107.8 M30.2 M
Slightly volatile
Total Liabilities44.7 M42.6 M9.6 M
Slightly volatile
Property Plant And Equipment Gross32.1 M30.6 M8.7 M
Slightly volatile
Total Current Assets4.9 M5.1 M11.1 M
Pretty Stable
Capital Stock3.8 KK12.8 M
Slightly volatile
Common Stock3.1 K5.1 K1.7 K
Slightly volatile
Property Plant Equipment13 M12.4 M4.7 M
Slightly volatile
Short and Long Term Debt Total16.5 M15.7 M4.2 M
Slightly volatile
Net Receivables827 K524 K1.9 M
Slightly volatile
Inventory1.5 M1.6 M907.1 K
Slightly volatile
Short Term Debt7.6 M7.3 M2.1 M
Slightly volatile
Long Term Debt7.4 M8.5 M6.6 M
Slightly volatile
Capital Surpluse66.4 M74.7 M81.5 M
Slightly volatile
Non Current Liabilities Other11.4 K12.8 K14 K
Slightly volatile
Short and Long Term Debt5.1 M5.7 M6.2 M
Slightly volatile

HCW Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income610.2 K581.2 K232.9 K
Slightly volatile
Depreciation And Amortization838.9 K1.4 M621.9 K
Slightly volatile
Selling General Administrative26.5 M25.2 M7.1 M
Slightly volatile
Other Operating Expenses20.7 M36.9 M13.9 M
Slightly volatile
Research DevelopmentM7.3 M6.2 M
Slightly volatile
Cost Of RevenueM1.8 MM
Slightly volatile
Total Operating Expenses19.1 M35 M13 M
Slightly volatile
Reconciled Depreciation840.6 K1.4 M622.6 K
Slightly volatile
Selling And Marketing Expenses577.8 K925.6 K338 K
Slightly volatile

HCW Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation644.9 K1.2 M314 K
Slightly volatile
Begin Period Cash Flow3.9 M4.1 M4.9 M
Slightly volatile
Depreciation838.9 K1.4 M621.9 K
Slightly volatile
Capital Expenditures285.8 K300.9 K1.9 M
Pretty Stable
Issuance Of Capital Stock11.6 M5.8 M13.3 M
Pretty Stable
End Period Cash Flow7.8 M4.2 MM
Very volatile
Dividends Paid2.3 M2.5 M2.8 M
Slightly volatile
Cash And Cash Equivalents Changes8.5 M9.5 M10.4 M
Slightly volatile
Cash Flows Other Operating1.9 M2.1 M2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2953101.6 K
Slightly volatile
Days Sales Outstanding14495.21177
Slightly volatile
Average Payables3.5 M3.3 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue0.180.350.0981
Slightly volatile
Capex To Depreciation0.190.23.26
Pretty Stable
EV To Sales2983141.6 K
Slightly volatile
Inventory Turnover2.372.672.9125
Slightly volatile
Days Of Inventory On Hand98.49111121
Slightly volatile
Payables Turnover0.07860.08281.1523
Pretty Stable
Sales General And Administrative To Revenue8.087.692.2257
Slightly volatile
Average Inventory558 K627.7 K685.2 K
Slightly volatile
Research And Ddevelopement To Revenue1.672.241.8438
Slightly volatile
Capex To Revenue0.08710.09170.3542
Slightly volatile
Cash Per Share0.130.140.2733
Pretty Stable
Days Payables Outstanding4.8 K4.6 K1.1 K
Slightly volatile
Income Quality1.030.540.9158
Pretty Stable
Current Ratio0.210.226.9277
Slightly volatile
Receivables Turnover6.65.074.0091
Slightly volatile
Capex Per Share0.00580.00610.0519
Pretty Stable
Average Receivables220.3 K247.8 K270.5 K
Slightly volatile
Revenue Per Share0.120.07610.1144
Very volatile
Interest Debt Per Share0.360.340.1059
Slightly volatile
Debt To Assets0.430.410.129
Slightly volatile
Operating Cycle17895.21194
Slightly volatile
Days Of Payables Outstanding4.8 K4.6 K1.1 K
Slightly volatile
Ebt Per Ebit0.790.920.9735
Slightly volatile
Long Term Debt To Capitalization11.4710.932.1624
Slightly volatile
Total Debt To Capitalization1.871.780.3916
Slightly volatile
Quick Ratio0.210.226.8999
Slightly volatile
Net Income Per E B T0.80.90.979
Slightly volatile
Cash Ratio0.170.185.3509
Slightly volatile
Days Of Inventory Outstanding98.49111121
Slightly volatile
Days Of Sales Outstanding14495.21177
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.00.921.1991
Pretty Stable
Fixed Asset Turnover0.120.131.7448
Slightly volatile
Debt Ratio0.430.410.129
Slightly volatile
Price Sales Ratio2953101.6 K
Slightly volatile
Asset Turnover0.170.09760.2158
Slightly volatile
Gross Profit Margin0.350.430.3737
Pretty Stable

HCW Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap756.1 M795.9 M2.7 B
Slightly volatile
Enterprise Value765.9 M806.2 M2.7 B
Slightly volatile

HCW Fundamental Market Drivers

HCW Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About HCW Biologics Financial Statements

HCW Biologics stakeholders use historical fundamental indicators, such as HCW Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in HCW Biologics' assets and liabilities are reflected in the revenues and expenses on HCW Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M2.2 M
Total RevenueM3.7 M
Cost Of Revenue1.8 MM
Stock Based Compensation To Revenue 0.35  0.18 
Sales General And Administrative To Revenue 7.69  8.08 
Research And Ddevelopement To Revenue 2.24  1.67 
Capex To Revenue 0.09  0.09 
Revenue Per Share 0.08  0.12 
Ebit Per Revenue(13.21)(13.87)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(16.41)
Revenue Per Share
0.68
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.30)
Return On Equity
(277.26)
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.